What is novel in the clinical management of pemphigus vulgaris?

References

• Zhou X, Zhan T, Xu X, et al. The efficacy and safety of low-dose rituximab in the treatment of pemphigus vulgaris: a cohort study. J DermatolTreat. 2024;35(1):2302071. doi: 10.1080/09546634.2024.2302071
   Google Scholar
• Tedbirt B, Maho-Vaillant M, Houivet E, et al. Sustained remission without corticosteroids among patients with pemphigus who had rituximab as first-line therapy: follow-up of the Ritux 3 trial. JAMA Dermatol. 2024;160(3):290–296. doi: 10.1001/jamadermatol.2023.5679
   PubMedGoogle Scholar
• Joly P, Horvath B, Patsatsi A, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the European academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol. 2020;34(9):1900–1913. doi: 10.1111/jdv.16752
   PubMed Web of Science ®Google Scholar
• Didona D, Schmidt MF, Maglie R, et al. Pemphigus and pemphigoids: clinical presentation, diagnosis and therapy. J Dtsch Dermatol Ges. 2023;21(10):1188–1209. doi: 10.1111/ddg.15174
   Web of Science ®Google Scholar
• Murrell DF. What is the true mortality from pemphigus? Br J Dermatol. 2016;174(6):1185–1186. doi: 10.1111/bjd.14711
   PubMed Web of Science ®Google Scholar
• Rizzo C, Fotino M, Zhang Y, et al. Direct characterization of human T cells in pemphigus vulgaris reveals elevated autoantigen-specific Th2 activity in association with active disease. Clin Exp Dermatol. 2005;30(5):535–540. doi: 10.1111/j.1365-2230.2005.01836.x
   PubMed Web of Science ®Google Scholar
• Haghighi Javid A, Li D, Technau-Hafsi K, et al. Interleukin-17A immune pattern across genetic acantholytic and blistering disorders. Clin Exp Dermatol. 2023;48(5):518–523. doi: 10.1093/ced/llad012
   PubMed Web of Science ®Google Scholar
• Polakova A, Kauter L, Ismagambetova A, et al. Detection of rare autoreactive T cell subsets in patients with pemphigus vulgaris. Front Immunol. 2022;13:979277. doi: 10.3389/fimmu.2022.979277
   PubMed Web of Science ®Google Scholar
• Yuan H, Zhou S, Liu Z, et al. Pivotal role of lesional and perilesional T/B lymphocytes in Pemphigus Pathogenesis. J Invest Dermatol. 2017;137(11):2362–2370. doi: 10.1016/j.jid.2017.05.032
   PubMed Web of Science ®Google Scholar
• Poulsen LK, Hummelshoj L. Triggers of IgE class switching and allergy development. Ann Med. 2007;39(6):440–456. doi: 10.1080/07853890701449354
   PubMed Web of Science ®Google Scholar
• Tsuboi H, Matsuo N, Iizuka M, et al. Analysis of IgG4 class switch-related molecules in IgG4-related disease. Arthritis Res Ther. 2012;14(4):R171. doi: 10.1186/ar3924
   PubMed Web of Science ®Google Scholar
• Casan JML, Wong J, Northcott MJ, et al. Anti-CD20 monoclonal antibodies: reviewing a revolution. Hum Vaccin Immunother. 2018;14(12):2820–2841. doi: 10.1080/21645515.2018.1508624
   PubMed Web of Science ®Google Scholar
• Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today. 1994;15(9):450–454. doi: 10.1016/0167-5699(94)90276-3
   PubMedGoogle Scholar
• Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol. 2006;177(1):362–371. doi: 10.4049/jimmunol.177.1.362
   PubMed Web of Science ®Google Scholar
• Zhang B. Ofatumumab. MAbs. 2009;1(4):326–331. doi: 10.4161/mabs.1.4.8895
   PubMed Web of Science ®Google Scholar
• Joly P, Maho-Vaillant M, Prost-Squarcioni C, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017;389(10083):2031–2040. doi: 10.1016/S0140-6736(17)30070-3
   PubMed Web of Science ®Google Scholar
• Kasperkiewicz M, Ellebrecht CT, Takahashi H, et al. Pemphigus. Nat Rev Dis Primers. 2017;3(1). doi: 10.1038/nrdp.2017.26
   PubMedGoogle Scholar
• Ellebrecht CT, Choi EJ, Allman DM, et al. Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris. JAMA Dermatol. 2014;150(12):1331. doi: 10.1001/jamadermatol.2014.1939
   PubMed Web of Science ®Google Scholar
• Crowley MP, McDonald V, Scully M. Ofatumumab for TTP in a patient with anaphylaxis associated with Rituximab. N Engl J Med. 2018;378(1):92–93. doi: 10.1056/NEJMc1714146
   PubMed Web of Science ®Google Scholar
• Rapp M, Pentland A, Richardson C. Successful treatment of pemphigus vulgaris with ofatumumab. J Drugs Dermatol. 2018;17(12):1338–1339.
   PubMed Web of Science ®Google Scholar
• Klufas DM, Amerson E, Twu O, et al. Refractory pemphigus vulgaris successfully treated with ofatumumab. JAAD Case Rep. 2020;6(8):734–736. doi: 10.1016/j.jdcr.2020.05.034
   PubMedGoogle Scholar
• Malik AM, Tupchong S, Huang S, et al. An updated review of pemphigus diseases. Medicina (Kaunas). 2021;57(10):1080. doi: 10.3390/medicina57101080
   PubMed Web of Science ®Google Scholar
• Mazloom E, Daneshpazhooh M, Shokouhi Shoormasti R, et al. Intralesional injection of biosimilar rituximab in recalcitrant mucocutaneous lesions of patients with pemphigus vulgaris: a pilot study. Dermatol Ther. 2020;33(6):e14407. doi: 10.1111/dth.14407
   PubMed Web of Science ®Google Scholar
• Cerny T, Borisch B, Introna M, et al. Mechanism of action of rituximab. Anticancer Drugs. 2002;13(Suppl 2):S3–10. doi: 10.1097/00001813-200211002-00002
   PubMed Web of Science ®Google Scholar
• Teeling JL, French RR, Cragg MS, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood. 2004;104(6):1793–1800. doi: 10.1182/blood-2004-01-0039
   PubMed Web of Science ®Google Scholar
• Craigen JL, Mackus WJM, Engleberts P, et al. Ofatumumab, a human mab targeting a membrane-proximal small-loop epitope on CD20, induces potent NK cell-mediated ADCC. Blood. 2009;114(22):1725–. doi: 10.1182/blood.V114.22.1725.1725
   PubMed Web of Science ®Google Scholar
• Pawluczkowycz AW, Beurskens FJ, Beum PV, et al. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J Immunol. 2009;183(1):749–758. doi: 10.4049/jimmunol.0900632
   PubMed Web of Science ®Google Scholar
• Sanford M, McCormack PL. Ofatumumab. Drugs. 2010;70(8):1013–1019. doi: 10.2165/11203850-000000000-00000
   PubMed Web of Science ®Google Scholar
• Zhang X, Xiao Y, Li X, et al. Ofatumumab subcutaneous injection successfully treated patients with pemphigus vulgaris relapse post rituximab. J Dermatol. 2024. doi: 10.1111/1346-8138.17108
   Web of Science ®Google Scholar
• Goldenberg DM, Rossi EA, Stein R, et al. Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood. 2009;113(5):1062–1070. doi: 10.1182/blood-2008-07-168146
   PubMed Web of Science ®Google Scholar
• Goldenberg DM, Morschhauser F, Wegener WA. Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. Leuk Lymphoma. 2010;51(5):747–755. doi: 10.3109/10428191003672123
   PubMed Web of Science ®Google Scholar
• Abulikemu K, Hu F, Liang J, et al. Targeting therapy in pemphigus: where are we now and where are we going? Heliyon. 2023;9(6):e16679. doi: 10.1016/j.heliyon.2023.e16679
   PubMed Web of Science ®Google Scholar
• Meyer S, Evers M, Jansen JHM, et al. New insights in type I and II CD20 antibody mechanisms-of-action with a panel of novel CD20 antibodies. Br J Haematol. 2018;180(6):808–820. doi: 10.1111/bjh.15132
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Cree BAC, Hauser SL. Ocrelizumab and other CD20(+) B-Cell-depleting therapies in multiple sclerosis. Neurotherapeutics. 2017;14(4):835–841. doi: 10.1007/s13311-017-0557-4
   PubMed Web of Science ®Google Scholar
• Capasso N, Nozzolillo A, Scalia G, et al. Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis. Mult Scler Relat Disord. 2021;49:102802. doi: 10.1016/j.msard.2021.102802
   PubMed Web of Science ®Google Scholar
• Benesh G, Andriano TM, Cohen SR. Pemphigus vulgaris successfully treated with ocrelizumab following rituximab allergy. JAAD Case Rep. 2021;16:12–15. doi: 10.1016/j.jdcr.2021.08.005
   PubMedGoogle Scholar
• de-la-Rosa-Fernandez E, Loizate-Sarrionandia I, Gonzalez-Rodriguez J, et al. Ocrelizumab, an alternative to rituximab in refractory pemphigus vulgaris management. J Eur Acad Dermatol Venereol. 2023;37(9):e1104–e6. doi: 10.1111/jdv.19133
   PubMed Web of Science ®Google Scholar
• Shipkova M, Wieland E. Surface markers of lymphocyte activation and markers of cell proliferation. Clin Chim Acta. 2012;413(17–18):1338–1349. doi: 10.1016/j.cca.2011.11.006
   PubMed Web of Science ®Google Scholar
• Tavakolpour S, Mahmoudi H, Mirzazadeh A, et al. Pathogenic and protective roles of cytokines in pemphigus: a systematic review. Cytokine. 2020;129:155026. doi: 10.1016/j.cyto.2020.155026
   PubMed Web of Science ®Google Scholar
• Renkl A, Mockenhaupt M, Technau K, et al. A novel therapeutic option in pemphigus vulgaris: humanized monoclonal anti-CD25 antibody. Br J Dermatol. 2004;150(6):1220–1222. doi: 10.1111/j.1365-2133.2004.05977.x
   PubMed Web of Science ®Google Scholar
• Assaf S, Malki L, Mayer T, et al. ST18 affects cell-cell adhesion in pemphigus vulgaris in a tumour necrosis factor-alpha-dependent fashion. Br J Dermatol. 2021;184(6):1153–1160. doi: 10.1111/bjd.19679
   PubMed Web of Science ®Google Scholar
• D’Auria L, Bonifati C, Mussi A, et al. Cytokines in the sera of patients with pemphigus vulgaris: interleukin-6 and tumour necrosis factor-alpha levels are significantly increased as compared to healthy subjects and correlate with disease activity. Eur Cytokine Netw. 1997;8(4):383–387.
   PubMed Web of Science ®Google Scholar
• Hennerici T, Pollmann R, Schmidt T, et al. Increased frequency of T follicular helper cells and elevated interleukin-27 plasma levels in patients with Pemphigus. PLoS One. 2016;11(2):e0148919. doi: 10.1371/journal.pone.0148919
   PubMed Web of Science ®Google Scholar
• Ameglio F, D’Auria L, Cordiali-Fei P, et al. Bullous pemphigoid and pemphigus vulgaris: correlated behaviour of serum VEGF, sE-selectin and TNF-alpha levels. J Biol Regul Homeost Agents. 1997;11(4):148–153.
   PubMed Web of Science ®Google Scholar
• Ameglio F, D’Auria L, Cordiali-Fei P, et al. Anti-intercellular substance antibody log titres are correlated with serum concentrations of interleukin-6, interleukin-15 and tumor necrosis factor-alpha in patients with pemphigus vulgaris relationships with peripheral blood neutrophil counts, disease severity and duration and patients’ age. J Biol Regul Homeost Agents. 1999;13(4):220–224.
   PubMed Web of Science ®Google Scholar
• Feliciani C, Toto P, Amerio P, et al. In vitro and in vivo expression of interleukin-1alpha and tumor necrosis factor-alpha mRNA in pemphigus vulgaris: interleukin-1alpha and tumor necrosis factor-alpha are involved in acantholysis. J Invest Dermatol. 2000;114(1):71–77. doi: 10.1046/j.1523-1747.2000.00835.x
   PubMed Web of Science ®Google Scholar
• López‐Robles E, Avalos‐Díaz E, Vega‐Memije E, et al. TNFα and IL‐6 are mediators in the blistering process of pemphigus. Int J Dermatol. 2001;40(3):185–188. doi: 10.1046/j.1365-4362.2001.01083.x
   PubMed Web of Science ®Google Scholar
• Khozeimeh F, Savabi O, Esnaashari M. Evaluation of interleukin-1alpha, interleukin-10, tumor necrosis factor-alpha and transforming growth factor-beta in the serum of patients with pemphigus vulgaris. J Contemp Dent Pract. 2014;15(6):746–749. doi: 10.5005/jp-journals-10024-1610
   PubMedGoogle Scholar
• Narbutt J, Lukamowicz J, Bogaczewicz J, et al. Serum concentration of interleukin-6 is increased both in active and remission stages of pemphigus vulgaris. Mediators Inflamm. 2008;2008:875394. doi: 10.1155/2008/875394
   PubMed Web of Science ®Google Scholar
• Lee SH, Hong WJ, Kim SC. Analysis of serum cytokine profile in Pemphigus. Ann Dermatol. 2017;29(4):438–445. doi: 10.5021/ad.2017.29.4.438
   PubMed Web of Science ®Google Scholar
• Timoteo RP, da Silva MV, Miguel CB, et al. Th1/Th17-related cytokines and chemokines and their implications in the pathogenesis of pemphigus vulgaris. Mediators Inflamm. 2017;2017:7151285. doi: 10.1155/2017/7151285
   PubMed Web of Science ®Google Scholar
• Kowalski EH, Kneibner D, Kridin K, et al. Serum and blister fluid levels of cytokines and chemokines in pemphigus and bullous pemphigoid. Autoimmun Rev. 2019;18(5):526–534. doi: 10.1016/j.autrev.2019.03.009
   PubMed Web of Science ®Google Scholar
• Pardo J, Mercader P, Mahiques L, et al. Infliximab in the management of severe pemphigus vulgaris. Br J Dermatol. 2005;153(1):222–223. doi: 10.1111/j.1365-2133.2005.06672.x
   PubMed Web of Science ®Google Scholar
• Gubinelli E, Bergamo F, Didona B, et al. Pemphigus foliaceus treated with etanercept. J Am Acad Dermatol. 2006;55(6):1107–1108. doi: 10.1016/j.jaad.2006.08.041
   PubMed Web of Science ®Google Scholar
• Vojackova N, Fialova J, Vanousova D, et al. Pemphigus vulgaris treated with adalimumab: case study. Dermatol Ther. 2012;25(1):95–97. doi: 10.1111/j.1529-8019.2012.01433.x
   PubMed Web of Science ®Google Scholar
• Andres TS, Alexandro B, de Oca-Sanchez Griselda M, et al. Etanercept plus methotrexate: an effective combination therapy for recalcitrant pemphigus vulgaris. J Res Med Sci. 2015;20(3):317. doi: 10.4103/1735-1995.156182
   PubMed Web of Science ®Google Scholar
• Didona D, Fania L, Di Zenzo G, et al. Erythromycin-induced pemphigus foliaceus successfully treated with etanercept. Dermatol Ther. 2020;33(6):e14201. doi: 10.1111/dth.14201
   PubMed Web of Science ®Google Scholar
• Kaya Erdogan H, Yuksel Canakci N, Acer E, et al. Successful treatment of pemphigus foliaceous and ankylosing spondylitis with infliximab and methotrexate: a case report. Dermatol Ther. 2020;33(4):e13801. doi: 10.1111/dth.13801
   PubMed Web of Science ®Google Scholar
• Daulat S, Detweiler JG, Pandya AG. Development of pemphigus vulgaris in a patient with psoriasis treated with etanercept. J Eur Acad Dermatol Venereol. 2009;23(4):483–484. doi: 10.1111/j.1468-3083.2008.02929.x
   PubMed Web of Science ®Google Scholar
• Hall RP 3rd, Fairley J, Woodley D, et al. A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone. Br J Dermatol. 2015;172(3):760–768. doi: 10.1111/bjd.13350
   PubMed Web of Science ®Google Scholar
• Nagata S, Golstein P. The Fas death factor. Science. 1995;267(5203):1449–1456. doi: 10.1126/science.7533326
   PubMed Web of Science ®Google Scholar
• Lotti R, Shu E, Petrachi T, et al. Soluble fas ligand is essential for blister formation in Pemphigus. Front Immunol. 2018;9:370. doi: 10.3389/fimmu.2018.00370
   PubMed Web of Science ®Google Scholar
• Kischkel FC, Hellbardt S, Behrmann I, et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. Embo J. 1995;14(22):5579–5588. doi: 10.1002/j.1460-2075.1995.tb00245.x
   PubMed Web of Science ®Google Scholar
• Lavrik I, Golks A, Krammer PH. Death receptor signaling. J Cell Sci. 2005;118(Pt 2):265–267. doi: 10.1242/jcs.01610
   PubMed Web of Science ®Google Scholar
• Altemeier WA, Zhu X, Berrington WR, et al. Fas (CD95) induces macrophage proinflammatory chemokine production via a MyD88-dependent, caspase-independent pathway. J Leukocyte Biol. 2007;82(3):721–728. doi: 10.1189/jlb.1006652
   PubMed Web of Science ®Google Scholar
• Orlov MD, Chernyavsky AI, Arredondo J, et al. Synergistic actions of pemphigus vulgaris IgG, fas-ligand and tumor necrosis factor-alpha during induction of basal cell shrinkage and acantholysis. Autoimmunity. 2006;39(7):557–562. doi: 10.1080/08916930600971729
   PubMed Web of Science ®Google Scholar
• Arredondo J, Chernyavsky AI, Karaouni A, et al. Novel mechanisms of target cell death and survival and of therapeutic action of IVIg in Pemphigus. Am J Pathol. 2005;167(6):1531–1544. doi: 10.1016/S0002-9440(10)61239-4
   PubMed Web of Science ®Google Scholar
• Lotti R, Hundt JE, Ludwig RJ, et al. Blocking soluble fas ligand ameliorates pemphigus: PC111 efficacy in ex-vivo human pemphigus models. Front Immunol. 2023;14:1193032. doi: 10.3389/fimmu.2023.1193032
   PubMed Web of Science ®Google Scholar
• Cauza K, Hinterhuber G, Dingelmaier-Hovorka R, et al. Expression of FcRn, the MHC class I-related receptor for IgG, in human keratinocytes. J Invest Dermatol. 2005;124(1):132–139. doi: 10.1111/j.0022-202X.2004.23542.x
   PubMed Web of Science ®Google Scholar
• Nelson CA, Tomayko MM. Targeting the FcRn: a novel approach to the treatment of Pemphigus. J Invest Dermatol. 2021;141(12):2777–2780. doi: 10.1016/j.jid.2021.06.035
   PubMed Web of Science ®Google Scholar
• Chen Y, Chernyavsky A, Webber RJ, et al. Critical role of the neonatal fc receptor (FcRn) in the pathogenic action of antimitochondrial autoantibodies synergizing with anti-desmoglein autoantibodies in pemphigus vulgaris. J Biol Chem. 2015;290(39):23826–23837. doi: 10.1074/jbc.M115.668061
   PubMed Web of Science ®Google Scholar
• Zakrzewicz A, Wurth C, Beckert B, et al. Stabilization of keratinocyte monolayer integrity in the presence of anti-desmoglein-3 antibodies through FcRn blockade with Efgartigimod: novel treatment paradigm for pemphigus? Cells. 2022;11(6):942. doi: 10.3390/cells11060942
   PubMed Web of Science ®Google Scholar
• Gornowicz-Porowska J, Kowalczyk MJ, Seraszek-Jaros A, et al. A comparative analysis of CD32A and CD16A polymorphisms in relation to autoimmune responses in Pemphigus diseases and subepithelial autoimmune blistering disorders. Genes (Basel). 2020;11(4):371. doi: 10.3390/genes11040371
   PubMed Web of Science ®Google Scholar
• Werth VP, Culton DA, Concha JSS, et al. Safety, tolerability, and activity of ALXN1830 targeting the neonatal fc receptor in chronic pemphigus. J Invest Dermatol. 2021;141(12):2858–65 e4. doi: 10.1016/j.jid.2021.04.031
   PubMed Web of Science ®Google Scholar
• Goebeler M, Bata-Csorgo Z, De Simone C, et al. Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal fc receptor inhibitor: a phase II multicentre, open-label feasibility trial. Br J Dermatol. 2022;186(3):429–439. doi: 10.1111/bjd.20782
   PubMed Web of Science ®Google Scholar
• Maho-Vaillant M, Sips M, Golinski ML, et al. FcRn antagonism leads to a decrease of desmoglein-specific B cells: secondary analysis of a phase 2 study of Efgartigimod in Pemphigus Vulgaris and Pemphigus Foliaceus. Front Immunol. 2022;13:863095. doi: 10.3389/fimmu.2022.863095
   PubMed Web of Science ®Google Scholar
• 2023 https://www.argenx.com/news/argenx-reports-topline-results-address-study-efgartigimod-sc-pemphigus Argenx reports topline results address study efgartigimod sc pemphigus
   Google Scholar
• Li N, Zhao M, Hilario-Vargas J, et al. Complete FcRn dependence for intravenous ig therapy in autoimmune skin blistering diseases. J Clin Invest. 2005;115(12):3440–3450. doi: 10.1172/JCI24394
   PubMed Web of Science ®Google Scholar
• Asashima N, Fujimoto M, Watanabe R, et al. Serum levels of BAFF are increased in bullous pemphigoid but not in pemphigus vulgaris. Br J Dermatol. 2006;155(2):330–336. doi: 10.1111/j.1365-2133.2006.07305.x
   PubMed Web of Science ®Google Scholar
• Dorner T, Posch MG, Li Y, et al. Treatment of primary Sjogren’s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity. Ann Rheum Dis. 2019;78(5):641–647. doi: 10.1136/annrheumdis-2018-214720
   PubMed Web of Science ®Google Scholar
• Hebert V, Maho-Vaillant M, Golinski ML, et al. Modifications of the BAFF/BAFF-Receptor axis in patients with pemphigus treated with rituximab versus standard corticosteroid regimen. Front Immunol. 2021;12:666022. doi: 10.3389/fimmu.2021.666022
   PubMed Web of Science ®Google Scholar
• Daneshvar E, Tavakolpour S, Mahmoudi H, et al. Elevated serum level of B-cell activating factor (BAFF) after rituximab therapy in pemphigus vulgaris patients suggests a possible therapeutic efficacy of B-cell depletion therapies combined with anti-BAFF agents. Int J Dermatol. 2023;62(4):567–574. doi: 10.1111/ijd.16363
   PubMed Web of Science ®Google Scholar
• Thien M, Phan TG, Gardam S, et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity. 2004;20(6):785–798. doi: 10.1016/j.immuni.2004.05.010
   PubMed Web of Science ®Google Scholar
• Torkamani N, Kamali Sarvestani E, Naseri M. Investigation of serum APRIL and BAFF levels in pemphigus vulgaris patients in southern Iran. Iran J Dermatol. 2011;14(1):16–19.
   Google Scholar
• Gandolfo S, De Vita S. Double anti-B cell and anti-BAFF targeting for the treatment of primary Sjögren’s syndrome. Clin Exp Rheumatol. 2019;37 Suppl 118(Suppl 3):199–208.
   PubMed Web of Science ®Google Scholar
• Ruan J, Zhang X, Zheng M. Belimumab for the treatment of pemphigus. Dermatologic Therapy. 2022;35(8). doi: 10.1111/dth.15621
   Web of Science ®Google Scholar
• Fetter T, Niebel D, Braegelmann C, et al. Skin-Associated B Cells in the pathogenesis of cutaneous autoimmune diseases—implications for therapeutic approaches. Cells. 2020;9(12):2627. doi: 10.3390/cells9122627
   PubMed Web of Science ®Google Scholar
• Patsatsi A, Murrell DF. Bruton Tyrosine Kinase Inhibition and its role as an emerging treatment in Pemphigus. Front Med. 2021;8:708071. doi: 10.3389/fmed.2021.708071
   Web of Science ®Google Scholar
• Langrish CL, Bradshaw JM, Francesco MR, et al. Preclinical efficacy and anti-inflammatory mechanisms of action of the Bruton Tyrosine Kinase inhibitor rilzabrutinib for immune-mediated disease. J Immunol. 2021;206(7):1454–1468. doi: 10.4049/jimmunol.2001130
   PubMed Web of Science ®Google Scholar
• Smith PF, Krishnarajah J, Nunn PA, et al. A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton’s tyrosine kinase, in healthy volunteers. Br J Clin Pharmacol. 2017;83(11):2367–2376. doi: 10.1111/bcp.13351
   PubMed Web of Science ®Google Scholar
• Lee A, Sandhu S, Imlay-Gillespie L, et al. Successful use of Bruton’s kinase inhibitor, ibrutinib, to control paraneoplastic pemphigus in a patient with paraneoplastic autoimmune multiorgan syndrome and chronic lymphocytic leukaemia. Australas J Dermatol. 2017;58(4):e240–e2. doi: 10.1111/ajd.12615
   PubMed Web of Science ®Google Scholar
• Ito Y, Makita S, Maeshima AM, et al. Paraneoplastic Pemphigus associated with B-cell chronic lymphocytic leukemia treated with ibrutinib and Rituximab. Intern Med. 2018;57(16):2395–2398. doi: 10.2169/internalmedicine.0578-17
   PubMed Web of Science ®Google Scholar
• Bradshaw JM, McFarland JM, Paavilainen VO, et al. Prolonged and tunable residence time using reversible covalent kinase inhibitors. Nat Chem Biol. 2015;11(7):525–531. doi: 10.1038/nchembio.1817
   PubMed Web of Science ®Google Scholar
• Stephens DM, Byrd JC. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood. 2019;133(12):1298–1307. doi: 10.1182/blood-2018-11-846808
   PubMed Web of Science ®Google Scholar
• Naik PP. Translational autoimmunity in pemphigus and the role of novel Bruton tyrosine kinase inhibitors. J Transl Autoimmun. 2022;5:100156. doi: 10.1016/j.jtauto.2022.100156
   PubMedGoogle Scholar
• Murrell DF, Patsatsi A, Stavropoulos P, et al. Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study. Br J Dermatol. 2021;185(4):745–755. doi: 10.1111/bjd.20431
   PubMed Web of Science ®Google Scholar
• Murrell DF, Caux F, Patsatsi A, et al. Efficacy and safety of Rilzabrutinib in Pemphigus: PEGASUS phase 3 randomized study. J Invest Dermatol. 2024. doi: 10.1016/j.jid.2024.02.023
   PubMedGoogle Scholar
• Goodale EC, Varjonen KE, Outerbridge CA, et al. Efficacy of a Bruton’s tyrosine kinase inhibitor (PRN-473) in the treatment of canine pemphigus foliaceus. Vet Dermatol. 2020;31(4):291–e71. doi: 10.1111/vde.12841
   PubMed Web of Science ®Google Scholar
• Yamagami J, Ujiie H, Aoyama Y, et al. A multicenter, open-label, uncontrolled, single-arm phase 2 study of tirabrutinib, an oral Bruton’s tyrosine kinase inhibitor, in pemphigus. J Dermatol Sci. 2021;103(3):135–142. doi: 10.1016/j.jdermsci.2021.07.002
   PubMed Web of Science ®Google Scholar
• Siddiqi HF, Staser KW, Nambudiri VE. Research techniques made simple: CAR T-Cell therapy. J Invest Dermatol. 2018;138(12):2501–4.e1. doi: 10.1016/j.jid.2018.09.002
   PubMed Web of Science ®Google Scholar
• Wang C, Wang J, Che S, et al. CAR-T cell therapy for hematological malignancies: history, status and promise. Heliyon. 2023;9(11):e21776. doi: 10.1016/j.heliyon.2023.e21776
   PubMed Web of Science ®Google Scholar
• Miao L, Zhang Z, Ren Z, et al. Reactions related to CAR-T cell therapy. Front Immunol. 2021;12:663201. doi: 10.3389/fimmu.2021.663201
   PubMedGoogle Scholar
• Rubin CB, Elenitsas R, Taylor L, et al. Evaluating the skin in patients undergoing chimeric antigen receptor modified T-cell therapy. J Am Acad Dermatol. 2016;75(5):1054–1057. doi: 10.1016/j.jaad.2016.06.062
   PubMed Web of Science ®Google Scholar
• Ghilardi G, Fraietta JA, Gerson JN, et al. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nature Med. 2024;30(4):984–989. doi: 10.1038/s41591-024-02826-w
   PubMedGoogle Scholar
• Lee J, Lundgren DK, Mao X, et al. Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris. J Clin Invest. 2020;130(12):6317–6324. doi: 10.1172/JCI138416
   PubMed Web of Science ®Google Scholar
• Ellebrecht CT, Bhoj VG, Nace A, et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science. 2016;353(6295):179–184. doi: 10.1126/science.aaf6756
   PubMed Web of Science ®Google Scholar
• Yamaoka K, Saharinen P, Pesu M, et al. The janus kinases (Jaks). Genome Biol. 2004;5(12):253. doi: 10.1186/gb-2004-5-12-253
   PubMed Web of Science ®Google Scholar
• Velazquez L, Fellous M, Stark GR, et al. A protein tyrosine kinase in the interferon alpha/beta signaling pathway. Cell. 1992;70(2):313–322. doi: 10.1016/0092-8674(92)90105-L
   PubMed Web of Science ®Google Scholar
• Macchi P, Villa A, Giliani S, et al. Mutations of jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature. 1995;377(6544):65–68. doi: 10.1038/377065a0
   PubMed Web of Science ®Google Scholar
• Samadi A, Ahmad Nasrollahi S, Hashemi A, et al. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature. J DermatolTreat. 2017;28(6):476–483. doi: 10.1080/09546634.2016.1277179
   Google Scholar
• Bao L, Zhang H, Chan LS. The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis. JAKSTAT. 2013;2(3):e24137. doi: 10.4161/jkst.24137
   PubMedGoogle Scholar
• Fukuyama T, Ehling S, Cook E, et al. Topically administered janus-kinase inhibitors tofacitinib and oclacitinib display impressive antipruritic and anti-inflammatory responses in a model of allergic dermatitis. J Pharmacol Exp Ther. 2015;354(3):394–405. doi: 10.1124/jpet.115.223784
   PubMed Web of Science ®Google Scholar
• Harel S, Higgins CA, Cerise JE, et al. Pharmacologic inhibition of JAK-STAT signaling promotes hair growth. Sci Adv. 2015;1(9):e1500973. doi: 10.1126/sciadv.1500973
   PubMed Web of Science ®Google Scholar
• Deeks ED, Duggan S. Abrocitinib: first approval. Drugs. 2021;81(18):2149–2157. doi: 10.1007/s40265-021-01638-3
   PubMed Web of Science ®Google Scholar
• Dhillon S. Delgocitinib: first approval. Drugs. 2020;80(6):609–615. doi: 10.1007/s40265-020-01291-2
   PubMed Web of Science ®Google Scholar
• Shawky AM, Almalki FA, Abdalla AN, et al. A comprehensive overview of globally approved JAK inhibitors. Pharmaceutics. 2022;14(5):1001. doi: 10.3390/pharmaceutics14051001
   PubMed Web of Science ®Google Scholar
• Juczynska K, Wozniacka A, Waszczykowska E, et al. Expression of JAK3, STAT2, STAT4, and STAT6 in pemphigus vulgaris. Immunol Res. 2020;68(2):97–103. doi: 10.1007/s12026-020-09122-y
   PubMed Web of Science ®Google Scholar
• Ociepa K, Danilewicz M, Wagrowska-Danilewicz M, et al. Expression of the selected proteins of JAK/STAT signaling pathway in diseases with oral mucosa involvement. Int J Mol Sci. 2022;24(1):323. doi: 10.3390/ijms24010323
   PubMed Web of Science ®Google Scholar
• Fan B, Wang M. Ruxolitinib, a JAK1/2 inhibitor as treatment for paraneoplastic pemphigus: a case report. Acta Derm Venereol. 2022;102:adv00732. doi: 10.2340/actadv.v102.1378
   PubMed Web of Science ®Google Scholar
• Wang L, Zhao B. Janus kinase inhibitor—tofacitinib associated with pemphigus: an analysis of the FDA adverse event reporting system data. Expert Opin Drug Saf. 2023;22(12):1–4. doi: 10.1080/14740338.2023.2248872
   PubMed Web of Science ®Google Scholar
• Koga T, Hedrich CM, Mizui M, et al. CaMK4-dependent activation of AKT/mTOR and CREM-α underlies autoimmunity-associated Th17 imbalance. J Clin Investig. 2014;124(5):2234–2245. doi: 10.1172/JCI73411
   PubMed Web of Science ®Google Scholar
• Yang J, Nie J, Ma X, et al. Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer. 2019;18(1). doi: 10.1186/s12943-019-0954-x
   Google Scholar
• Pretel M, España A, Marquina M, et al. An imbalance in Akt/mTOR is involved in the apoptotic and acantholytic processes in a mouse model of pemphigus vulgaris. Exp Dermatol. 2009;18(9):771–780. doi: 10.1111/j.1600-0625.2009.00893.x
   PubMed Web of Science ®Google Scholar
• Espana A, Modol T, Gil MP, et al. Neural nitric oxide synthase participates in pemphigus vulgaris acantholysis through upregulation of Rous sarcoma, mammalian target of rapamycin and focal adhesion kinase. Exp Dermatol. 2013;22(2):125–130. doi: 10.1111/exd.12088
   PubMed Web of Science ®Google Scholar
• Lai K, Zhang W, Li S, et al. mTOR pathway regulates the differentiation of peripheral blood Th2/Treg cell subsets in patients with pemphigus vulgaris. Acta Biochim Biophys Sin (Shanghai). 2021;53(4):438–445. doi: 10.1093/abbs/gmab008
   PubMed Web of Science ®Google Scholar
• Pombo-Suarez M, Gomez-Reino JJ. Abatacept for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2019;15(4):319–326. doi: 10.1080/1744666X.2019.1579642
   PubMed Web of Science ®Google Scholar
• Lorenzetti R, Janowska I, Smulski CR, et al. Abatacept modulates CD80 and CD86 expression and memory formation in human B-cells. J Autoimmun. 2019;101:145–152. doi: 10.1016/j.jaut.2019.04.016
   PubMed Web of Science ®Google Scholar
• Sweet BV. Abatacept. Am J Health Syst Pharm. 2006;63(21):2065–2077. doi: 10.2146/ajhp060200
   PubMed Web of Science ®Google Scholar
• Alenazy MF, Saheb Sharif-Askari F, Omair MA, et al. Abatacept enhances blood regulatory B cells of rheumatoid arthritis patients to a level that associates with disease remittance. Sci Rep. 2021;11(1). doi: 10.1038/s41598-021-83615-0
   Web of Science ®Google Scholar
• McCormick SM, Heller NM. Commentary: IL-4 and IL-13 receptors and signaling. Cytokine. 2015;75(1):38–50. doi: 10.1016/j.cyto.2015.05.023
   PubMed Web of Science ®Google Scholar
• Tavakolpour S, Tavakolpour V. Interleukin 4 inhibition as a potential therapeutic in pemphigus. Cytokine. 2016;77:189–195. doi: 10.1016/j.cyto.2015.09.017
   PubMed Web of Science ®Google Scholar
• Russo R, Cozzani E, Gasparini G, et al. Targeting interleukin 4 receptor alpha: a new approach to the treatment of cutaneous autoimmune bullous diseases? Dermatol Ther. 2020;33(1):e13190. doi: 10.1111/dth.13190
   PubMed Web of Science ®Google Scholar
• Lin MS, Swartz SJ, Lopez A, et al. Development and characterization of desmoglein-3 specific T cells from patients with pemphigus vulgaris. J Clin Invest. 1997;99(1):31–40. doi: 10.1172/JCI119130
   PubMed Web of Science ®Google Scholar
• Rico MJ, Benning C, Weingart ES, et al. 3rd. Characterization of skin cytokines in bullous pemphigoid and pemphigus vulgaris. Br J Dermatol. 1999;140(6):1079–1086. doi: 10.1046/j.1365-2133.1999.02907.x
   PubMed Web of Science ®Google Scholar
• Caproni M, Giomi B, Cardinali C, et al. Further support for a role for Th2-like cytokines in blister formation of pemphigus. Clin Immunol. 2001;98(2):264–271. doi: 10.1006/clim.2000.4974
   PubMed Web of Science ®Google Scholar
• Satyam A, Khandpur S, Sharma VK, et al. Involvement of T(H)1/T(H)2 cytokines in the pathogenesis of autoimmune skin disease-Pemphigus vulgaris. Immunol Invest. 2009;38(6):498–509. doi: 10.1080/08820130902943097
   PubMed Web of Science ®Google Scholar
• Toumi A, Abida O, Ben Ayed M, et al. Cytokine gene polymorphisms in Tunisian endemic pemphigus foliaceus: a possible role of il-4 variants. Hum Immunol. 2013;74(5):658–665. doi: 10.1016/j.humimm.2013.01.009
   PubMed Web of Science ®Google Scholar
• Chen S, Zhan S, Hua C, et al. A novel combined use of dupilumab for treatment of aggressive refractory pemphigus vulgaris complicated with pulmonary tuberculosis: a case report and the RNA-seq analysis. Front Immunol. 2022;13:825796. doi: 10.3389/fimmu.2022.825796
   PubMed Web of Science ®Google Scholar
• Jiang C, Adjei S, Santiago S, et al. Novel use of dupilumab in pemphigus vulgaris and pemphigus foliaceus. JAAD Case Rep. 2023;42:12–15. doi: 10.1016/j.jdcr.2023.09.018
   PubMedGoogle Scholar
• Moore AY, Hurley K. Dupilumab monotherapy suppresses recalcitrant pemphigus vulgaris. JAAD Case Rep. 2023;31:16–18. doi: 10.1016/j.jdcr.2022.10.035
   PubMedGoogle Scholar
• Shen F, Gaffen SL. Structure-function relationships in the IL-17 receptor: implications for signal transduction and therapy. Cytokine. 2008;41(2):92–104. doi: 10.1016/j.cyto.2007.11.013
   PubMed Web of Science ®Google Scholar
• Arakawa M, Dainichi T, Yasumoto S, et al. Lesional Th17 cells in pemphigus vulgaris and pemphigus foliaceus. J Dermatol Sci. 2009;53(3):228–231. doi: 10.1016/j.jdermsci.2008.09.008
   PubMed Web of Science ®Google Scholar
• Xu R-C, Zhu H-Q, Li W-P, et al. The imbalance of Th17 and regulatory T cells in pemphigus patients. Eur J Dermatol. 2013;23(6):795–802. doi: 10.1684/ejd.2013.2177
   PubMed Web of Science ®Google Scholar
• Xue J, Su W, Chen Z, et al. Overexpression of interleukin-23 and interleukin-17 in the lesion of pemphigus vulgaris: a preliminary study. Mediators Inflamm. 2014;2014:463928. doi: 10.1155/2014/463928
   PubMed Web of Science ®Google Scholar
• Zebrowska A, Wozniacka A, Juczynska K, et al. Correlation between IL36alpha and IL17 and activity of the disease in selected autoimmune blistering diseases. Mediators Inflamm. 2017;2017:8980534. doi: 10.1155/2017/8980534
   PubMed Web of Science ®Google Scholar
• Ben Jmaa M, Abida O, Fakhfakh R, et al. Involvement of the IL23/Th17 pathway in the pathogenesis of Tunisian Pemphigus Foliaceus. Mediators Inflamm. 2018;2018:8206983. doi: 10.1155/2018/8206983
   PubMed Web of Science ®Google Scholar
• Huang Z-X, Qu P, Wang K-K, et al. Transcriptomic profiling of pemphigus lesion infiltrating mononuclear cells reveals a distinct local immune microenvironment and novel lncRNA regulators. J Transl Med. 2022;20(1). doi: 10.1186/s12967-022-03387-7
   Web of Science ®Google Scholar
• Gholibeigian Z, Izad M, Daneshpazhooh M, et al. Decreased serum levels of interleukin-17, interleukin-23, TGF-beta in pemphigus vulgaris patients, and their association with disease phase. Dermatol Ther. 2020;33(6):e14071. doi: 10.1111/dth.14071
   PubMed Web of Science ®Google Scholar
• Joshi N, Minz RW, Anand S, et al. Vitamin D deficiency and lower TGF-β/IL-17 ratio in a North Indian cohort of pemphigus vulgaris. BMC Res Notes. 2014;7(1):536. doi: 10.1186/1756-0500-7-536
   PubMedGoogle Scholar
• Singh PK, Das S, Rai G, et al. A snapshot of T cell subset cytokines in Pemphigus Vulgaris: a cross-sectional study. Cureus. 2022. doi: 10.7759/cureus.29890
   Web of Science ®Google Scholar
• Holstein J, Solimani F, Baum C, et al. Immunophenotyping in pemphigus reveals a T(H)17/T(FH)17 cell-dominated immune response promoting desmoglein1/3-specific autoantibody production. J Allergy Clin Immunol. 2021;147(6):2358–2369. doi: 10.1016/j.jaci.2020.11.008
   PubMed Web of Science ®Google Scholar
• Lin X, Chen M, Li X, et al. Low SOCS3 expression in CD4+ T cells from pemphigus vulgaris patients enhanced Th1- and Th17-cell differentiation and exacerbated acantholysis via STAT activation. Mol Immunol. 2022;150:114–125. doi: 10.1016/j.molimm.2022.08.007
   PubMed Web of Science ®Google Scholar
• Ansari MA, Singh PK, Dar SA, et al. Deregulated phenotype of autoreactive Th17 and treg clone cells in pemphigus vulgaris after in-vitro treatment with desmoglein antigen (dsg-3). Immunobiology. 2023;228(2):152340. doi: 10.1016/j.imbio.2023.152340
   PubMed Web of Science ®Google Scholar
• Schauer F, Meiss F, Thoma K, et al. IL17 inhibition for psoriasis vulgaris and arthritis results in clinical and serological remission of coexistent pemphigus foliaceus. J Dermatol. 2021;48(6):e246–e7. doi: 10.1111/1346-8138.15801
   PubMed Web of Science ®Google Scholar
• Kohlmann J, Simon JC, Kunz M, et al. Possible effect of interleukin-17 blockade in pemphigus foliaceus and neutrophilic diseases. Hautarzt. 2019;70(8):641–644. doi: 10.1007/s00105-019-4414-8
   PubMed Web of Science ®Google Scholar
• Morishima-Koyano M, Nobeyama Y, Fukasawa-Momose M, et al. Case of pemphigus foliaceus misdiagnosed as a single condition of erythrodermic psoriasis and modified by brodalumab. J Dermatol. 2020;47(5):e201–e2. doi: 10.1111/1346-8138.15295
   PubMed Web of Science ®Google Scholar
• Ohata C, Shimizu Y, Hayashi M. Pemphigus foliaceus in a patient with psoriasis treated with brodalumab. J Dermatol. 2020;47(12):e455–e7. doi: 10.1111/1346-8138.15584
   PubMed Web of Science ®Google Scholar
• Alecu M, Alecu S, Coman G, et al. ICAM-1, ELAM-1, TNF-alpha and IL-6 in serum and blister liquid of pemphigus vulgaris patients. Roum Arch Microbiol Immunol. 1999;58(2):121–130.
   PubMedGoogle Scholar
• Mortazavi H, Babaeijandaghi F, Akbarzadeh M, et al. The influence of systemic therapy on the serum levels of IL‐6 and IL‐8 in pemphigus vulgaris. J Eur Acad Dermatol Venereol. 2011;27(3):387–390. doi: 10.1111/j.1468-3083.2011.04319.x
   PubMed Web of Science ®Google Scholar
• Pereira NF, Hansen JA, Lin MT, et al. Cytokine gene polymorphisms in endemic pemphigus foliaceus: a possible role for IL6 variants. Cytokine. 2004;28(6):233–241. doi: 10.1016/j.cyto.2004.08.006
   PubMed Web of Science ®Google Scholar
• Mosaad YM, Fathy H, Fawzy Z, et al. Tumor necrosis factor-alpha -308 G>A and interleukin-6 -174 G>C promoter polymorphisms and pemphigus. Hum Immunol. 2012;73(5):560–565. doi: 10.1016/j.humimm.2012.02.001
   PubMed Web of Science ®Google Scholar
• Caso F, Iaccarino L, Bettio S, et al. Refractory pemphigus foliaceus and Behçet’s disease successfully treated with tocilizumab. Immunol Res. 2013;56(2–3):390–397. doi: 10.1007/s12026-013-8411-1
   PubMed Web of Science ®Google Scholar
• Andrew K, Dhariwal SK, Szczecinska W. Sarilumab (interleukin-6 receptor monoclonal antibody) for the treatment of pemphigus vulgaris. Clin Exp Dermatol. 2023;48(9):1055–1056. doi: 10.1093/ced/llad173
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Miyara M, Costantino CM, et al. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol. 2010;10(7):490–500. doi: 10.1038/nri2785
   PubMed Web of Science ®Google Scholar
• Awasthi A, Kuchroo VK. Th17 cells: from precursors to players in inflammation and infection. Int Immunol. 2009;21(5):489–498. doi: 10.1093/intimm/dxp021
   PubMed Web of Science ®Google Scholar
• Cao X, Cai SF, Fehniger TA, et al. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity. 2007;27(4):635–646. doi: 10.1016/j.immuni.2007.08.014
   PubMed Web of Science ®Google Scholar
• Pandiyan P, Zheng L, Ishihara S, et al. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol. 2007;8(12):1353–1362. doi: 10.1038/ni1536
   PubMed Web of Science ®Google Scholar
• Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science. 2008;322(5899):271–275. doi: 10.1126/science.1160062
   PubMed Web of Science ®Google Scholar
• Josefowicz SZ, Niec RE, Kim HY, et al. Extrathymically generated regulatory T cells control mucosal TH2 inflammation. Nature. 2012;482(7385):395–399. doi: 10.1038/nature10772
   PubMed Web of Science ®Google Scholar
• Hsieh CS, Lee HM, Lio CW. Selection of regulatory T cells in the thymus. Nat Rev Immunol. 2012;12(3):157–167. doi: 10.1038/nri3155
   PubMed Web of Science ®Google Scholar
• Buckner JH. Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol. 2010;10(12):849–859. doi: 10.1038/nri2889
   PubMed Web of Science ®Google Scholar
• Selck C, Dominguez-Villar M. Antigen-Specific Regulatory T Cell Therapy in autoimmune diseases and transplantation. Front Immunol. 2021;12:12. doi: 10.3389/fimmu.2021.661875
   Web of Science ®Google Scholar
• Nishikawa H, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Curr Opin Immunol. 2014;27:1–7. doi: 10.1016/j.coi.2013.12.005
   PubMed Web of Science ®Google Scholar
• Didona D, Maglie R, Eming R, et al. Pemphigus: Current and future therapeutic strategies. Front Immunol. 2019;10:1418. doi: 10.3389/fimmu.2019.01418
   PubMed Web of Science ®Google Scholar
• Abd El-Magid WM, Ahmed SF, Assaf H, et al. Immunohistochemical expression of regulatory T cells (CD(4) (+) CD(25) (+) bright FOXP(3) (+)) in pemphigus patients. J Cosmet Dermatol. 2022;21(10):4871–4876. doi: 10.1111/jocd.14854
   PubMed Web of Science ®Google Scholar
• Yokoyama T, Matsuda S, Takae Y, et al. Antigen-independent development of Foxp3+ regulatory T cells suppressing autoantibody production in experimental pemphigus vulgaris. Int Immunol. 2011;23(6):365–373. doi: 10.1093/intimm/dxr020
   PubMed Web of Science ®Google Scholar
• Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354(17):1813–1826. doi: 10.1056/NEJMra052638
   PubMed Web of Science ®Google Scholar
• Gyurkocza B, Sandmaier BM. Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood. 2014;124(3):344–353. doi: 10.1182/blood-2014-02-514778
   PubMed Web of Science ®Google Scholar
• Oyama Y, Parker ER, Brieva J, et al. High-dose immune suppression and autologous hematopoietic stem cell transplantation in refractory pemphigus foliaceus. Bone Marrow Transplant. 2004;34(12):1097–1098. doi: 10.1038/sj.bmt.1704679
   PubMed Web of Science ®Google Scholar
• Suslova IM, Theodoropoulos DS, Cullen NA, et al. Pemphigus vulgaris treated with allogeneic hematopoietic stem cell transplantation following non-myeloablative conditioning. Eur Rev Med Pharmacol Sci. 2010;14(9):785–788.
   PubMed Web of Science ®Google Scholar
• Vanikar A, Trivedi H, Patel R, et al. Allogenic hematopoietic stem cell transplantation in pemphigus vulgaris: a single-center experience. Indian J Dermatol. 2012;57(1):9. doi: 10.4103/0019-5154.92667
   PubMedGoogle Scholar
• Wang M, Cao C, Sun J, et al. Application of autologous hematopoietic stem cell transplantation for pemphigus. Int J Dermatol. 2017;56(3):296–301. doi: 10.1111/ijd.13461
   PubMed Web of Science ®Google Scholar
• Khandpur S, Gupta S, Gunaabalaji DR. Stem cell therapy in dermatology. Indian J Dermatol Venereol Leprol. 2021;87:753–767. doi: 10.25259/IJDVL_19_20
   PubMed Web of Science ®Google Scholar
• Yuan H, Pan M, Chen H, et al. Immunotherapy for pemphigus: present and future. Front Med. 2022;9:901239. doi: 10.3389/fmed.2022.901239
   Web of Science ®Google Scholar
• Kim AR, Han D, Choi JY, et al. Targeting inducible costimulator expressed on CXCR5(+)PD-1(+) T(H) cells suppresses the progression of pemphigus vulgaris. J Allergy Clin Immunol. 2020;146(5):1070–9 e8. doi: 10.1016/j.jaci.2020.03.036
   PubMed Web of Science ®Google Scholar
• Aoki-Ota M, Kinoshita M, Ota T, et al. Tolerance induction by the blockade of CD40/CD154 interaction in pemphigus vulgaris mouse model. J Invest Dermatol. 2006;126(1):105–113. doi: 10.1038/sj.jid.5700016
   PubMed Web of Science ®Google Scholar
• Mao X, Sano Y, Park JM, et al. p38 MAPK activation is downstream of the loss of intercellular adhesion in pemphigus vulgaris. J Biol Chem. 2011;286(2):1283–1291. doi: 10.1074/jbc.M110.172874
   PubMed Web of Science ®Google Scholar
• Musette P, Bouaziz JD. B cell modulation strategies in autoimmune diseases: new concepts. Front Immunol. 2018;9:622. doi: 10.3389/fimmu.2018.00622
   PubMed Web of Science ®Google Scholar
• Koga H, Tsutsumi M, Teye K, et al. Subcorneal pustular dermatosis-type IgA pemphigus associated with multiple myeloma: a case report and literature review. J Dermatol. 2023;50(2):234–238. doi: 10.1111/1346-8138.16516
   PubMed Web of Science ®Google Scholar
• Frampton JE. Rituximab: a review in pemphigus vulgaris. Am J Clin Dermatol. 2020;21(1):149–156. doi: 10.1007/s40257-019-00497-9
   PubMed Web of Science ®Google Scholar
• Mustin DE, Cole EF, Leibowitz R, et al. Comparing clinical outcomes of steroid-sparing therapy with rituximab versus rituximab alone in Pemphigus. J Drugs Dermatol. 2024;23(3):e97–e9. doi: 10.36849/jdd.7949
   PubMedGoogle Scholar